^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma

Excerpt:
...we developed a human PDX model (SS110) from a resected ICC harboring an IDH1 R132C mutation...Established SS110 tumors (passage 2) were allowed to reach ~900 mm3 and then treated with dasatinib for 7 days...dasatinib had only minimal effects on the growth of an IDH WT ICC PDX.
DOI:
10.1158/2159-8290.CD-15-1442